Auxilium

News

This section provides essential news and information about Auxilium.

  • Press Releases - get the latest corporate information about Auxilium
  • Archive - see a complete listing of past press releases about Auxilium
  • Investor Kit - contact us to receive the latest investor relations information

For Investors - additional information and resources designed with investors in mind.

Recent News
DateTitle 
Apr 14, 2014Auxilium and Sobi Announce Encore Presentation of XIAFLEX/Xiapex Data at European Association of Urology Congress
Encore Data Highlighted from Trials Evaluating XIAFLEX, the First and Only FDA Approved Treatment for Peyronie's Disease CHESTERBROOK, Pa. and STOCKHOLM, April 14, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) and Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that encore data were presented from multiple clinical trials evaluating the use of XIAFLEX®/ Xiapex® (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). These ... 
Printer Friendly Version
Apr 7, 2014Sobi Becomes Market Authorisation Holder For Xiapex in Europe
STOCKHOLM and CHESTERBROOK, Pa., April 7, 2014 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) and Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced  that Sobi became the Market Authorisation Holder (MAH) for Xiapex® (collagenase clostridium histolyticum), in 28 EU member countries, Norway, and Iceland on April 3, 2014. Xiapex/ XIAFLEX® is a first-in-class biologic approved in the US, EU, Canada and Australia for the treatment of adult Dupuytren's contracture patients w... 
Printer Friendly Version
Mar 4, 2014Auxilium Pharmaceuticals, Inc. To Present At The Barclay's Global Healthcare Conference
CHESTERBROOK, Pa., March 4, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced that certain members of the executive management team will participate in the Barclay's Global Healthcare Conference to be held March 11-13, 2014 at the Loews Hotel in Miami. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product portfolio at 3:45 p.m. ET on Tuesday,... 
Printer Friendly Version
Feb 28, 2014Auxilium Pharmaceuticals Announces Fourth Quarter And Full Year 2013 Financial Results And Guidance For 2014
FY 2013 Net Revenues of $400.7 Million, a 32% Increase Over 2012 Non-GAAP Net Revenues FY 2013 Non-GAAP EPS Grew 77% to $0.62 2014 Guidance for Net Revenues of $450 - $490 Million CHESTERBROOK, Pa., Feb. 28, 2014 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a fully integrated specialty biopharmaceutical company, today announced financial results for the fourth quarter and full year ending December 31, 2013. The Company also highlighted select commercial, regulatory a... 
Printer Friendly Version